D.E. Shaw & Co
TNXP icon

D.E. Shaw & Co’s Tonix Pharmaceuticals TNXP Stock Holding History

D.E. Shaw & Co’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8
Closed -$1.15M – 5778
2022
Q1 		$1.15M Sell
8
-21
-72% -$3.21M ﹤0.01% 3785
2021
Q4 		$6.68M Buy
29
+19
+190% +$6.04M 0.01% 2072
2021
Q3 		$4.02M Buy
10
+9
+900% +$4.38M ﹤0.01% 2333
2021
Q2 		$834K Buy
+1
New +$735K ﹤0.01% 3690
2016
Q4 		– Hold
0
– -$82K – 3598
2016
Q3 		– Hold
0
– – – 3298
2016
Q2 		– Hold
0
– – – 3046
2016
Q1 		– Hold
0
– – – 3004
2015
Q4 		– Hold
0
– – – 3012
2015
Q3 		– Hold
0
– – – 3370

Other funds holding TNXP

M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

D.E. Shaw & Co's TNXP Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Tonix Pharmaceuticals (TNXP) in Q2 2022, closing a stake of 8 shares — an estimated $1.15M sold.

D.E. Shaw & Co first reported a position in TNXP in Q2 2021 and held it in 4 quarters. The position peaked at $6.68M in Q4 2021. 23 funds tracked by Wall St. Rank hold TNXP as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Tonix Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 8 Tonix Pharmaceuticals shares in Q2 2022, an estimated $1.15M.
  • D.E. Shaw & Co first reported a position in Tonix Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • D.E. Shaw & Co's Tonix Pharmaceuticals position peaked at $6.68M in Q4 2021.
  • 23 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.